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Abstract. The polypharmacy side effect prediction problem considers
cases in which two drugs taken individually do not result in a partic-
ular side effect; however, when the two drugs are taken in combina-
tion, the side effect manifests. In this work, we demonstrate that multi-
relational knowledge graph completion achieves state-of-the-art results
on the polypharmacy side effect prediction problem. Empirical results
show that our approach is particularly effective when the protein targets
of the drugs are well-characterized. In contrast to prior work, our ap-
proach provides more interpretable predictions and hypotheses for wet
lab validation.
Keywords: Knowledge graph · embedding · side effect prediction.
1 Introduction
Disease and other health-related problems are often treated with medication.
In many cases, though, multiple medications may be given to treat either a
single condition or to account for co-morbidities. However, such combinations
significantly increase the risk of unintended side effects due to unknown drug-
drug interactions.
In this work, we show that multi-relational knowledge graph (KG) completion
gives state-of-the-art performance in predicting these unknown drug-drug inter-
actions. The KGs are multi-relational in the sense that they contain edges with
different types. We formulate the problem as a multi-relational link prediction
problem in a KG and adapt existing graph embedding strategies to predict the
interactions. In contrast to prior approaches for the polypharmacy side effect
problem, we incorporate interpretable features; thus, our approach naturally
yields explainable predictions and suggests hypotheses for wet lab validation.
Further, while we focus on the side effect prediction problem, our approach is
general and can be applied to any multi-relational link prediction problem.
Much recent work has considered the problem of predicting drug-drug in-
teractions (e.g. [2,13] and probabilistic approaches like [9]). However, these ap-
proaches only consider whether an interaction occurs; they do not consider the
type of interaction as we do here. Thus, these methods are not directly compara-
ble. The recently-proposed Decagon approach [14] is most similar to ours; they
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Count
Proteins 19 089
Drugs 645
Protein-protein interactions 715 612
Drug-drug interactions 4 649 441
Drug-protein target relationships 11 501
Mono side effects 174 977
Distinct mono side effects 10 184
Distinct polypharmacy side effects 963
Table 1. Size statistics of the graph
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Fig. 1. Types of relational features.
also predict types of drug-drug interactions. However, they use a complicated
combination of a graph convolutional network and a tensor factorization. In con-
trast, we use a neural KG embedding method in combination with a method to
incorporate rule-based features. Hence, our method explicitly captures meaning-
ful relational features. Empirically, we demonstrate that our method outperforms
Decagon in Section 4.
2 Datasets
We use the publicly-available, preprocessed version of the dataset used in [14].1
It consists of a multi-relational knowledge graph with two main components: a
protein-protein and a drug-drug interaction network. Known drug-protein tar-
get relationships connect these different components. The protein-protein inter-
actions are derived from several existing sources; it is filtered to include only
experimentally-validated physical interactions in human. The drug-drug inter-
actions are extracted from the TWOSIDES database [11]. The drug-protein tar-
get relationships are experimentally-verified interactions from the STITCH [10]
database. Finally, the SIDER [6] and OFFSIDES [11] databases were used to
identify mono side effects of each drug. Please see Table 1 for detailed statistics
of the size and density of each part of the graph. For more details, please see [14].
Each drug-drug link corresponds to a particular polypharmacy side effect. Our
goal will be to predict missing drug-drug links.
3 Methods
KG embedding methods learn vector representations for entities and relation
types of a KG [1]. We investigate the performance of DistMult [12], a commonly-
used KG embedding method whose symmetry assumption is well-suited to this
problem due to the symmetric nature of the drug-drug (polypharmacy side ef-
fect) relation type. The advantage of KG embedding methods are their efficiency
and their ability to learn fine-grained entity types suitable for downstream tasks
without hand-crafted rules.These embedding methods, however, are less inter-
pretable than rule-based approaches and cannot incorporate domain knowledge.
A relational feature is a logical rule which is evaluated in the KG to deter-
mine its truth value. For instance, the formula (drug1, hasTarget, protein1) ∧
(drug2, hasTarget, protein1) corresponds to a binary feature which has value
1 if both drug1 and drug2 have protein1 as a target, and 0 otherwise. In
1 Available at http : //snap.stanford.edu/decagon
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this work, we leverage relational features modeling drug targets with the re-
lation type hasTarget and protein-protein interactions with the relation type
interactsWith. Figure 1 depicts the two features types we use in our polyphar-
macy model. For a pair of entities (h, t), the relational feature vector is denoted
by r(h,t). Relational features capture concrete relationships between entities;
thus, as shown in Section 4, they offer explanations for our predictions.
KBlrn is a recently proposed framework for end-to-end learning of knowl-
edge graph representations [4]. It learns a product of experts (PoE) [5] where
each expert is responsible for one feature type. In the context of KG represen-
tation learning, the goal is to train a PoE that assigns high probability to true
triples and low probabilities to triples assumed to be false. Let d = (h, r, t) be a
triple. The specific experts we use are defined as
f(r,L)(d | θ(r,L)) =
{
exp((eh ∗ et) ·wr)
1 for all r′ 6= r and f(r,R)(d | θ(r,R)) =
{
exp
(
r(h,t) ·wrrel
)
1 for all r′ 6= r
where ∗ is the element-wise product, · is the dot product, eh and et are the em-
bedding of the head and tail entity, respectively, and wr,wrrel are the parameter
vectors for the embedding and relational features for relation type r. The prob-
ability of triple d = (h, r, t) is now
p(d | θ) = f(r,L)(d | θ(r,L)) f(r,R)(d | θ(r,R))∑
c f(r,L)(c | θ(r,L)) f(r,R)(c | θ(r,R))
,
where c indexes all possible triples. As proposed in previous work, we approxi-
mate the gradient of the log-likelihood by performing negative sampling [4].
4 Experimental results
We now empirically evaluate our proposed approach based on multi-relational
knowledge graph completion to predict polypharmacy side effects.
Dataset construction We follow the common experimental design previously
used [14] to construct our dataset. The knowledge graph only contains “positive”
examples for which polypharmacy side effects exist. Thus, we create a set of
negative examples by randomly selecting a pair of drugs and a polypharmacy
side effect which does not exist in the knowledge graph. We ensure that the
number of positive and negative examples of each polypharmacy side effect are
equal. We then use stratified sampling to split the records in training, validation
and testing sets.
We use an instance of the relational feature types depicted in Figure 1 if
it occurs at least 10 times in the KG. We choose these relational feature types
because they offer a biological explanation for polypharmacy side effects; namely,
a polypharmacy side effect may manifest due to unexpected combinations or
interactions on the drug targets.
Baselines We first compare our proposed approach to Decagon [14]. Second, we
consider each drug as a binary vector of indicators for each mono side effect and
gene target. We construct training, validation and testing sets by concatenating
the vectors of the pairs of drugs described above. We predict the likelihood of
each polypharmacy side effect given the concatenated vectors.
4 B. Malone et al.
Complete Decagon dataset We first consider the same setting considered pre-
viously [14]. As shown in Table 2(top), our simple baseline, DistMult, and
KBlrn all outperform Decagon.
Drug-drug interactions only Next, we evaluate polypharmacy side effect predic-
tion based solely on the pattern of other polypharmacy side effects. Specifically,
we completely remove the drug-protein targets and protein-protein interactions
from the KG; thus, we use only the drug-drug polypharmacy side effects in
the training set for learning. We focus on DistMult and KBlrn since they
outperformed the other methods in the first setting.
Surprisingly, the results in Table 2(middle) show that both DistMult and
KBlrn perform roughly the same (or even improve slightly) in this setting,
despite discarding presumably-valuable drug target information. However, as
shown in Table 1, few drugs have annotated protein targets. Thus, we hypothe-
size that the learning algorithms ignore this information due to its sparsity.
Drugs with protein targets only To test this hypothesis, we remove all drugs
which do not have any annotated protein targets from the KG (and the associ-
ated triples from the dataset). That is, the drug target information is no longer
“sparse”, in that all drugs in the resulting KG have protein targets.
The results in Table 2(bottom) paint a very different picture than before;
KBlrn significantly outperforms DistMult. These results show that the com-
bination of learned (or embedding) features and relational features can signifi-
cantly improve performance when the relational features are present in the KG.
Explanations and hypothesis generation The relational features allow us to ex-
plain predictions and generate new hypotheses for wet lab validation. We chose
one of our high-likelihood predictions and “validated” it via literature evidence.
In particular, the ranking of the drug combination CID115237 (paliperidone)
and CID271 (calcium) for the side effect “pain” increased from 24 223 when
using only the embedding features (of 58 029 pairs of drugs for which “pain”
is not a known side effect) to a top-ranked pair when also using the relational
features. Inspection of the relational features shows that the interaction be-
tween lysophosphatidic acid receptor 1 (LPAR1) and matrix metallopeptidase
2 (MMP2) is particularly important for this prediction. The MMP family is
known to be associated with inflammation (pain) [7]. Independently, calcium
already upregulates MMP2 [8]. Paliperidone upregulates LPAR1, which in turn
has been shown to promote MMP activiation [3]. Thus, palperidone indirectly
exacerbates the up-regulation of MMP2 already caused by calcium; this, then,
leads to increased pain. Hence, the literature confirms our prediction discovered
due to the relational features.
5 Discussion
We have shown that multi-relational knowledge graph completion can achieve
state-of-the-art performance on the polypharmacy side effect prediction problem.
Further, relational features offer explanations for our predictions; they can then
be validated via the literature or wetlab. In the future, we plan to extend this
work by considering additional features of nodes in the graph, such as Gene
Ontology annotations for the proteins and chemical structure of the drugs.
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Method AuROC AuPR AP@50
Baseline 0.896 0.859 0.812
Decagon (values reported in [14]) 0.872 0.832 0.803
DistMult 0.923 0.898 0.899
KBlrn 0.899 0.878 0.857
DistMult (drug-drug interactions only) 0.931 0.909 0.919
KBlrn (drug-drug interactions only) 0.894 0.886 0.892
DistMult (drugs with protein targets only) 0.534 0.545 0.394
KBlrn (drugs with protein targets only) 0.829 0.797 0.774
Table 2. The performance of each approach on the pre-defined test set. The measures
are: area under the receiver operating characteristic curve (AuROC), area under the
precision-recall curve (AuPR), and the average precision for the top 50 predictions for
each polypharmacy side effect (AP@50). The best result within each group is in bold.
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